Gut Motility Pharmacology

Gut motility pharmacology encompasses the drug classes used to modulate movement of content through the gastrointestinal tract. Five principal categories exist: laxatives, prokinetics, anti-motility drugs, anti-spasmodics, and anti-emetics.

Stool consistency is governed by water absorption in the large intestine. Water reabsorption is passive and follows the osmotic gradient set by luminal ion concentrations. High ion concentrations drive greater water reabsorption, producing firmer stool, while low ion concentrations yield looser stool. Slow motility prolongs mucosal contact time, increasing water absorption and causing constipation; rapid motility reduces contact time, causing diarrhoea.

Peristalsis is coordinated by the enteric nervous system. Enterochromaffin cells lining the gut epithelium release serotonin (5-HT) in response to mechanical distension. Released 5-HT binds to 5-HT1 and 5-HT4 receptors on intrinsic primary afferent neurons (IPANs) in the myenteric plexus, generating action potentials. These neurons release acetylcholine (ACh) onto smooth muscle behind the food bolus, driving coordinated propulsive contraction. Dopamine, acting at D2 receptors on myenteric neurons, inhibits ACh release and therefore slows peristalsis, providing a counterbalancing brake to prevent intestinal obstruction when two boluses of different sizes are present simultaneously.

The GIT also produces opioid neuropeptides—enkephalins, endorphins, and dynorphins—that modulate motility and pain perception at the local level.

Dopamine D2 receptor antagonists (e.g., metoclopramide) are the most clinically important prokinetic class. By blocking D2 receptors on myenteric neurons they disinhibit ACh release, increasing peristalsis in a rhythmically coordinated fashion. This is superior to muscarinic agonists or acetylcholinesterase inhibitors, which cause diffuse simultaneous contraction without propulsion. Metoclopramide additionally blocks D2 receptors in the chemoreceptor trigger zone (CTZ) and is therefore simultaneously an anti-emetic.

Nausea and vomiting can be triggered by three pathways: direct stimulation of the vomiting centre by vagal afferents (via 5-HT3 receptors), stimulation through the CTZ (which monitors blood for noxious substances via D2 receptors), and direct histamine H1 receptor activation on the vomiting centre—explaining the efficacy of antihistamines in motion sickness. Ondansetron, a 5-HT3 antagonist, blocks the vagal afferent pathway and is widely used for chemotherapy-induced emesis.